|
Info: |
Array BioPharma Inc., a
biopharmaceutical company, focuses on the
discovery, development, and commercialization of
small molecule drugs to treat patients afflicted
with cancer and inflammatory diseases in North
America, Europe, and the Asia Pacific. Its
programs under development include ARRY-520, a
kinesin spindle protein inhibitor in Phase 2
clinical trial for patients with multiple
myeloma; ARRY-614, a p38/Tie-2 dual inhibitor in
Phase 1 clinical trial for patients with
myelodysplastic syndrome; ARRY-380, a HER2
inhibitor in Phase 1 clinical trial for breast
cancer; ARRY-797, a p38 inhibitor in Phase 2
clinical trial for pain; and ARRY-502, a CRTh2
antagonist in Phase 1 clinical trial for
allergic inflammation. The company�s partnered
drugs in clinical development comprise
Selumetinib and AZD8330 MEK inhibitors for
cancer in Phase 2 trial; MEK162 and MEK300 MEK
inhibitors for cancer in Phase 2 trial;
Danoprevir, a Hepatitis C virus protease
inhibitor in Phase 2 trial; ARRY-543, a HER2/EGFR
inhibitor in Phase 2 trial for solid tumors; and
LY2603618, a ChK-1 inhibitor in Phase 2 trial
for cancer. Its partnered drugs in clinical
development also include AMG 151, a glucokinase
activator in Phase 1b trial for Type 2 diabetes;
GDC-0068, a AKT inhibitor in Phase 1b trial for
cancer; VTX-2337, a toll-like receptor in Phase
1b trial for cancer; VTX-1463, a toll-like
receptor in Phase 1b trial for allergy;
ARRY-382, a cFMS inhibitor in Phase 1 trial for
cancer; and ARRY-575 and GDC-0425, which are
ChK-1 inhibitors in Phase 1 trial for cancer.
The company has collaborations with Amgen, Inc.;
ASLAN Pharmaceuticals Pte Ltd.; AstraZeneca,
PLC; Celgene Corporation; Genentech, Inc.;
Novartis International Pharmaceutical Ltd.;
InterMune, Inc.; Eli Lilly and Company; and
VentiRx Pharmaceuticals, Inc for the development
and commercialization of the partnered drugs.
Array BioPharma Inc. was founded in 1998 and is
headquartered in Boulder, Colorado. |
|
Share Info: |
There are
89.14 million shares outstanding with
62.79 million shares in the trading float.
Institutions own approximately 71.60% of
the shares outstanding. There have been 2
insider purchases totaling 183,853 shares and
4 insider sales totaling 6,938
shares
in the last six months.
Real-Time SEC Filings
As of 6/29/2012, there were
4.11 million shares short.
Net Institutional Buying: 16.56
million shares
most recent quarter |
